Experienced in Leydig Cell Testicular Tumor

Dr. Lakshmanan Krishnamurti

Hematology | Oncology
1405 Clifton Rd Ne, 
Atlanta, GA 
Accepting New Patients
Experienced in Leydig Cell Testicular Tumor
1405 Clifton Rd Ne, 
Atlanta, GA 
OverviewInsuranceLocationsClinical Research

Overview

Lakshmanan Krishnamurti is a Hematologist and an Oncologist in Atlanta, Georgia. Dr. Krishnamurti is rated as an Experienced provider by MediFind in the treatment of Leydig Cell Testicular Tumor. His top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, Hemolytic Anemia, and Bone Marrow Transplant. Dr. Krishnamurti is currently accepting new patients.

His clinical research consists of co-authoring 117 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Leydig Cell Testicular Tumor.

Specialties
Hematology
Oncology
Licenses
Specialist in GA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 4 Less Insurance Carriers -

Locations

1405 Clifton Rd Ne, Atlanta, GA 30322

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 1/2, Open-label, Single-arm Study to Assess the Safety, Tolerability, and Efficacy of ST-400 Autologous Hematopoietic Stem Cell Transplant for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)
A Phase 1/2, Open-label, Single-arm Study to Assess the Safety, Tolerability, and Efficacy of ST-400 Autologous Hematopoietic Stem Cell Transplant for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)
Enrollment Status: Completed
Publish Date: December 14, 2023
Intervention Type: Genetic
Study Drug: BCL11A-Positive CD34-Positive Hematopoietic Stem Cells
Study Phase: Phase 1/Phase 2
Phase I/II Study of CaspaCIDe T Cells (BPX-501; Rivogenlecleucel) From an HLA Partially Matched Family Donor After Negative Selection of TCRαβ+ T Cells in Paediatric Patients Affected by Haematological Disorders
Phase I/II Study of CaspaCIDe T Cells (BPX-501; Rivogenlecleucel) From an HLA Partially Matched Family Donor After Negative Selection of TCRαβ+ T Cells in Paediatric Patients Affected by Haematological Disorders
Enrollment Status: Terminated
Publish Date: September 29, 2023
Intervention Type: Biological, Drug
Study Drugs: Rivogenlecleucel, Rimiducid
Study Phase: Phase 1/Phase 2
Phase I/II Study of CaspaCIDe® T Cells From an HLA-Partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders
Phase I/II Study of CaspaCIDe® T Cells From an HLA-Partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders
Enrollment Status: Active_not_recruiting
Publish Date: July 12, 2022
Intervention Type: Biological, Drug
Study Drugs: BPX-501 T Cells, Rimiducid
Study Phase: Phase 1/Phase 2
Pediatric Blood & Marrow Transplant Consortium (PBMTC) Phase II Myeloablative Haploidentical BMT With Post-transplantation Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
Pediatric Blood & Marrow Transplant Consortium (PBMTC) Phase II Myeloablative Haploidentical BMT With Post-transplantation Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: November 26, 2021
Intervention Type: Radiation, Other, Drug
Study Phase: Phase 2
Efficacy of a Decision Aid for Hydroxyurea(HU) in Sickle Cell Disease(SCD)
Efficacy of a Decision Aid for Hydroxyurea(HU) in Sickle Cell Disease(SCD)
Enrollment Status: Terminated
Publish Date: July 23, 2019
Intervention Type: Other
Study Phase: Not Applicable
View 4 Less Clinical Trials

117 Total Publications

Informed Shared Decision-Making or Rigid Eligibility and Exclusion Criteria for Gene Therapy for Sickle Cell Disease?
Informed Shared Decision-Making or Rigid Eligibility and Exclusion Criteria for Gene Therapy for Sickle Cell Disease?
Journal: Blood advances
Published: April 29, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Krishnamurti's expertise for a condition
ConditionClose
    View All 17 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile